IRIS
GROSSI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.635
AS - Asia 659
NA - Nord America 616
Continente sconosciuto - Info sul continente non disponibili 124
SA - Sud America 54
AF - Africa 11
OC - Oceania 1
Totale 5.100
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 3.538
US - Stati Uniti d'America 579
SG - Singapore 218
CN - Cina 140
BD - Bangladesh 128
VN - Vietnam 118
FR - Francia 39
BR - Brasile 32
HK - Hong Kong 23
DE - Germania 15
GB - Regno Unito 11
CA - Canada 9
FI - Finlandia 7
AR - Argentina 6
JP - Giappone 6
UA - Ucraina 6
HN - Honduras 5
JM - Giamaica 5
MX - Messico 5
VE - Venezuela 5
CR - Costa Rica 4
IN - India 4
PH - Filippine 4
SV - El Salvador 4
ID - Indonesia 3
PL - Polonia 3
PY - Paraguay 3
SA - Arabia Saudita 3
TR - Turchia 3
TW - Taiwan 3
BS - Bahamas 2
CH - Svizzera 2
CO - Colombia 2
DZ - Algeria 2
EC - Ecuador 2
KE - Kenya 2
MY - Malesia 2
NL - Olanda 2
RS - Serbia 2
SE - Svezia 2
UY - Uruguay 2
AL - Albania 1
AU - Australia 1
BE - Belgio 1
CL - Cile 1
CV - Capo Verde 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
IE - Irlanda 1
IQ - Iraq 1
KG - Kirghizistan 1
LC - Santa Lucia 1
LV - Lettonia 1
MA - Marocco 1
MU - Mauritius 1
PE - Perù 1
PK - Pakistan 1
PR - Porto Rico 1
RE - Reunion 1
RO - Romania 1
RU - Federazione Russa 1
SI - Slovenia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 4.976
Salva come PNG Salva come JPEG
Città #
Genova 1.476
Genoa 1.190
Rapallo 451
Vado Ligure 335
Singapore 102
San Jose 94
Ashburn 80
Ho Chi Minh City 36
Lauterbourg 33
New York 26
Hanoi 25
Beijing 22
Hong Kong 22
St Louis 20
Los Angeles 18
Santa Clara 17
Frankfurt am Main 13
Buffalo 12
Council Bluffs 12
Bordighera 10
Chicago 7
Milan 7
Helsinki 6
Rome 6
São Paulo 6
City of London 5
Houston 5
Tokyo 5
Atlanta 4
Da Nang 4
Dallas 4
Garland 4
Kingston 4
Mexico City 4
Orlando 4
Philadelphia 4
Queens 4
San José 4
San Salvador 4
Biên Hòa 3
Boardman 3
Cincinnati 3
Fort Lauderdale 3
Haiphong 3
Hải Dương 3
Jackson 3
Kansas City 3
Kyiv 3
Las Vegas 3
Naples 3
Orem 3
Paris 3
Pittsburgh 3
Tegucigalpa 3
Toronto 3
Warsaw 3
Ancona 2
Asunción 2
Bari 2
Belgrade 2
Brownsville 2
Bình Dương 2
Cagliari 2
Cardiff 2
Cerritos 2
Cleveland 2
Columbus 2
Davao City 2
Durham 2
Greenville 2
Hoover 2
Horn Lake 2
Houma 2
Istanbul 2
Jacksonville 2
Janesville 2
Jeddah 2
Lawrenceville 2
Leander 2
Lexington 2
Marseille 2
Messina 2
Miami 2
Mississauga 2
Montesilvano 2
Nairobi 2
Nassau 2
Ninh Bình 2
Palermo 2
Phủ Lý 2
Resistencia 2
Richmond 2
Seattle 2
Spring Hill 2
Springfield 2
Sterling Heights 2
Stockholm 2
Taipei 2
Thái Nguyên 2
Toms River 2
Totale 4.224
Salva come PNG Salva come JPEG
Nome #
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 204
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 201
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 180
Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely 180
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 162
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab 157
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 148
Liquid biopsy in non-small cell lung cancer: Highlights and challenges 143
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography? 140
Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients 137
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 137
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 136
Afatinib for the treatment of non-small cell lung cancer 136
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 135
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 135
Exosomes: a new horizon in lung cancer 131
Gefitinib treatment outcome after progression on erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) 127
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 125
Difference in skin toxicity incidence between erlotinib and gefitinib in the treatment of advanced non-small-cell lung cancer (NSCLC) 121
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 121
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 116
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds 116
Understanding the checkpoint blockade in lung cancer immunotherapy 112
Disease stabilization as a surrogate end point in advanced non small cell lung cancer patients treated with erlotinib or gefitinib 111
Recent advances in squamous non-small cell lung cancer: Evidence beyond predictive biomarkers 108
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 105
Hematopoietic growth factors in lung cancer 105
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy 105
Vinflunine for the treatment of non-small cell lung cancer 103
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer 96
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 93
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects 89
Skin toxicities difference between erlotinib and gefitinib in the treatment of advanced non-small-cell lung cancer (NSCLC) 89
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis 89
PCSK9 is a promising prognostic marker in patients with advanced NSCLC 88
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy 88
Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer 76
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression 69
Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: Can we use enemy territory at our advantage? 67
Reply to the Letter to the Editor by C. Nicolazzo et al.: “Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy” 65
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial 60
Looking for results in non-small-cell lung cancer: Is bio-chemotherapy the right answer? 49
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study 47
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 34
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 32
PCSK9 as a new player in cancer: New opportunity or red herring? 14
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial 11
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 7
Totale 5.100
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.086
article - articoli 19.384
book - libri 0
conference - conferenze 1.702
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.172
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022482 60 16 5 22 30 51 10 103 26 60 24 75
2022/2023514 42 34 9 51 85 94 0 43 78 6 67 5
2023/2024256 7 29 7 41 20 47 20 19 12 14 2 38
2024/2025877 22 52 30 53 121 92 101 185 30 48 67 76
2025/20261.649 192 30 82 84 221 111 233 54 140 179 163 160
2026/2027219 219 0 0 0 0 0 0 0 0 0 0 0
Totale 5.100